Pharmaceutical Product Monograph: Ceftazidime Sodium (1 g, 2 g)

In the pharmaceutical industry, Ceftazidime is a parenteral, semi-synthetic Third-Generation Cephalosporin antibiotic. As a pharmacist and manufacturer, I view this molecule as the "Anti-Pseudomonal Specialist"—it is technically designed with a complex side chain that gives it superior activity against Pseudomonas aeruginosa compared to almost any other cephalosporin.

At your WHO-GMP facility in Mumbai, Ceftazidime is a critical "Institutional SKU" for ICU and Critical Care portfolios. It is the primary weapon for hospital-acquired infections where Gram-negative "Superbugs" are suspected.

Therapeutic Profile: Primary Indications

Ceftazidime is indicated for severe infections where Gram-negative bacteria, particularly Pseudomonas, are the likely cause.

Indication Clinical Context Technical Rationale
Hospital-Acquired Pneumonia VAP / HAP Gold Standard: Effectively targets Pseudomonas and Klebsiella in ventilator-dependent patients.
Febrile Neutropenia Oncology / Hematology Often used as monotherapy to treat unexplained fever in cancer patients with low white cell counts.
Bacterial Meningitis CNS Infection Excellent CSF penetration (when meninges are inflamed), specifically for Gram-negative meningitis.
Complicated UTI Pyelonephritis / Sepsis Used for severe kidney infections or post-urological surgery complications.
Cystic Fibrosis Respiratory Crisis Used for the management of recurrent pulmonary infections in CF patients.
Septicemia Bloodstream Infection Used as empirical therapy for patients in septic shock.

Mechanism: Cell Wall Transpeptidase Inhibition

Ceftazidime works by sabotaging the structural integrity of the bacterial "outer shell":

PBP High Affinity: The drug enters the bacterial cell and binds with high affinity to Penicillin-Binding Proteins (PBPs), specifically PBP-3.

Peptidoglycan Blockade: It inhibits the final cross-linking (transpeptidation) step of cell wall synthesis.

Filamentation & Lysis: Technically, this leads to the formation of long, unstable bacterial filaments that cannot divide and eventually undergo osmotic lysis (the cell bursts).

The Pharmacist's "Technical Warning"

  • The "Pseudomonas" Paradox: As a pharmacist, I must emphasize that while Ceftazidime is an elite Gram-negative killer, it has very poor activity against Gram-positive bacteria like Staph. aureus (MSSA/MRSA). It should not be used as monotherapy if a "Staph" infection is suspected.

  • Renal Adjustment: Ceftazidime is excreted almost entirely unchanged by the kidneys. For patients with a $GFR < 50 \text{ mL/min}$, the dose must be reduced to prevent neurotoxicity (confusion, tremors).

  • The "L-Arginine" Note: Many formulations (including yours in Mumbai) use L-Arginine to stabilize the pH. This is technically safer than Sodium Carbonate as it prevents the release of excessive $CO_2$ gas during reconstitution.

  • Incompatibility: Never mix Ceftazidime and Aminoglycosides (like Amikacin or Gentamicin) in the same IV bag; they will physically precipitate and neutralize each other.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The "Aseptic Powder" USP: On your digital marketplace, highlight your Sterile Crystallization and Aseptic Filling. Ceftazidime is highly sensitive; ensuring zero moisture in the vial is the technical key to maintaining a 24-month shelf life.

  • The "Oncology Tendon" Advantage: Market Ceftazidime specifically to International Cancer Centers. Its status as a preferred agent for neutropenic sepsis makes it a high-volume, recurring revenue SKU for oncology procurement.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Ceftazidime 1 g and 2 g vials to support your registration in international B2B tenders for hospital and critical care.